BCR-ABL1 tyrosine kinase inhibitors (TKIs) are broadly applied in the treatment of BCR-ABL1-positive CML, particularly in the chronic phase.22 Five TKIs (imatinib, dasatinib, nilotinib, bosutinib, ponatinib, and radotinib) are currently worldwide approved, among which imatinib (Gleevec or STI571) is the first generation TKI and a strong competitive inhibitor of ATP binding to ABL1 kinase. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.